Medical equipment manufacturer Xylyx Bio, Inc. announced on Monday that it has received a USD2.45m Small Business Innovation Research (SBIR) grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to advance its InMatrico platform for liver fibrosis drug testing.
This platform aims to improve the discovery and testing of drug candidates for liver fibrosis, a process linked to several chronic liver diseases, including alcohol-associated and metabolic dysfunction-associated steatotic liver diseases.
With MASLD affecting 100 million people in the US and limited efficacy from approved treatments, there is a critical need for better drug testing models. InMatrico integrates patient-derived fibrotic liver extracellular matrix and key liver cells to address this gap. The award will support the platform's further development, enhancing drug discovery for fibrotic liver disease.
NCI reports IND submission for pilot study of Senhwa Biosciences Inc's developed Pidnarulex
MinervaX and Wacker Biotech collaborate on GBS vaccine manufacturing
Xylyx Bio receives SBIR grant from NIDDK
Anervea.ai names new chief commercial officer and board member
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
ValiRx subsidiary Inaphaea signs co-marketing agreement with Spanios
Sareum Holdings secures patent allowance for SDC-1801 in China
TME Pharma presents promising NOX-A12 trial results at ESMO Congress 2024
Kine Sciences reports first patient dosed in KINE-101 Phase 1b/2a clinical study
Senhwa Biosciences' Silmitasertib gains rare paediatric disease designation for Neuroblastoma
Lilly expands manufacturing footprint in Ireland
Sanofi, RadioMedix and Orano Med partner on rare cancer treatment
Johnson & Johnson receives approval from FDA for TREMFYA (guselkumab)
NeoGenomics to present breakthrough data at ESMO 2024 on ctDNA and NGS for cancer diagnostics